

Arantxa Gutierrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1932501/publications.pdf>

Version: 2024-02-01

40
papers

3,297
citations

201674

27
h-index

289244

40
g-index

40
all docs

40
docs citations

40
times ranked

4962
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo temporal resolution of acute promyelocytic leukemia progression reveals a role of <i>Klf4</i> in suppressing early leukemic transformation. <i>Genes and Development</i> , 2022, 36, 451-467.	5.9	1
2	Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 655201.	3.7	7
3	The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation. <i>Science Advances</i> , 2020, 6, eabb2745.	10.3	20
4	EPOP Functionally Links Elongin and Polycomb in Pluripotent Stem Cells. <i>Molecular Cell</i> , 2016, 64, 645-658.	9.7	117
5	Direct interaction between <i>Id1</i> and <i>Zrf1</i> controls neural differentiation of embryonic stem cells. <i>EMBO Reports</i> , 2015, 16, 63-70.	4.5	29
6	<i>Zrf1</i> is required to establish and maintain neural progenitor identity. <i>Genes and Development</i> , 2014, 28, 182-197.	5.9	29
7	<i>ZRF1</i> controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia. <i>Oncogene</i> , 2014, 33, 5501-5510.	5.9	22
8	Role of <i>UTX</i> in Retinoic Acid Receptor-Mediated Gene Regulation in Leukemia. <i>Molecular and Cellular Biology</i> , 2014, 34, 3765-3775.	2.3	24
9	<i>ZRF1</i> controls oncogene-induced senescence through the <i>INK4-ARF</i> locus. <i>Oncogene</i> , 2013, 32, 2161-2168.	5.9	30
10	The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 114-120.	3.8	25
11	<i>DPY30</i> regulates pathways in cellular senescence through <i>ID</i> protein expression. <i>EMBO Journal</i> , 2013, 32, 2217-2230.	7.8	32
12	E-box-independent regulation of transcription and differentiation by <i>MYC</i> . <i>Nature Cell Biology</i> , 2011, 13, 1443-1449.	10.3	37
13	DNA Methylation of the Gonadal Aromatase (<i>cyp19a</i>) Promoter Is Involved in Temperature-Dependent Sex Ratio Shifts in the European Sea Bass. <i>PLoS Genetics</i> , 2011, 7, e1002447.	3.5	457
14	<i>ER1</i> as ligand-independent activator of <i>CDH-1</i> regulates determination and maintenance of epithelial morphology in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7420-7425.	7.1	43
15	The histone variant macroH2A is an epigenetic regulator of key developmental genes. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 1074-1079.	8.2	166
16	<i>MBD3</i> , a Component of the NuRD Complex, Facilitates Chromatin Alteration and Deposition of Epigenetic Marks. <i>Molecular and Cellular Biology</i> , 2008, 28, 5912-5923.	2.3	106
17	Polycomb Complex 2 Is Required for <i>E-cadherin</i> Repression by the <i>Snail1</i> Transcription Factor. <i>Molecular and Cellular Biology</i> , 2008, 28, 4772-4781.	2.3	390
18	<i>PML4</i> induces differentiation by <i>Myc</i> destabilization. <i>Oncogene</i> , 2007, 26, 3415-3422.	5.9	35

#	ARTICLE	IF	CITATIONS
19	Role of the Polycomb Repressive Complex 2 in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2007, 11, 513-525.	16.8	228
20	The methyl-CpG binding protein MBD1 is required for PML-RAR α function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1400-1405.	7.1	93
21	Myc represses transcription through recruitment of DNA methyltransferase corepressor. <i>EMBO Journal</i> , 2005, 24, 336-346.	7.8	375
22	Altered epigenetic signals in human disease. <i>Cancer Biology and Therapy</i> , 2004, 3, 831-837.	3.4	19
23	Epigenetic gene silencing in acute promyelocytic leukemia. <i>Biochemical Pharmacology</i> , 2004, 68, 1247-1254.	4.4	29
24	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. <i>Virology</i> , 2003, 305, 318-329.	2.4	70
25	HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. <i>Antiviral Research</i> , 2003, 59, 137-142.	4.1	63
26	Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. <i>Journal of Virology</i> , 2003, 77, 4389-4395.	3.4	23
27	Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness. <i>Journal of Virology</i> , 2003, 77, 9069-9073.	3.4	77
28	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. <i>Antiviral Therapy</i> , 2003, 8, 155-161.	1.0	25
29	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. <i>Antiviral Therapy</i> , 2003, 8, 1-8.	1.0	51
30	Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+T Cells. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 27-38.	1.1	12
31	Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. <i>Aids</i> , 2002, 16, 2385-2390.	2.2	197
32	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. <i>Antiviral Research</i> , 2002, 53, 1-8.	4.1	31
33	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. <i>Virology</i> , 2001, 285, 356-365.	2.4	19
34	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. <i>Aids</i> , 2001, 15, 1890-1892.	2.2	15
35	Anti-Human Immunodeficiency Virus Activity of Novel Aminoglycoside-Arginine Conjugates at Early Stages of Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 627-634.	1.1	36
36	A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1132-1139.	3.2	27

#	ARTICLE	IF	CITATIONS
37	Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. <i>Molecular Pharmacology</i> , 1999, 55, 67-73.	2.3	107
38	Resistance of the Human Immunodeficiency Virus to the Inhibitory Action of Negatively Charged Albumins on Virus Binding to CD4. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1535-1543.	1.1	22
39	Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. <i>Journal of Virology</i> , 1999, 73, 5577-5585.	3.4	90
40	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). <i>Molecular Pharmacology</i> , 1998, 53, 340-345.	2.3	118